title: [Relevance of fluoroquinolone use in Nancy's hospital. Results of the first turn].
abstract: OBJECTIVE
  The objective was to evaluate the good use of fluoroquinolones in a hospital with a relevance review in the context of an approach to evaluation of professional practices at the regional level initiated by the Antibiolor network.
  
  
  METHODS
  In February 2008, in each volunteer service, practitioners filled out a standardized form indicating indication, the name of the fluoroquinolone, route of administration and duration of treatment, retrospectively from 20 medical records on the last 3 months. Each one was analyzed by a binomial (doctors and pharmacists) according to the local Antibioguide. The degree of compliance requirements has been appreciated by a global index of adequacy of therapeutic consisting of six criteria.
  
  
  RESULTS
  Eighteen units of Nancy's hospital filled 475 cards. The most frequent indications were pulmonary infections (38 %; 181/475) and urinary (23 %; 111/475). The fluoroquinolone indication was non-conform for 28 % of the cards (133/475). When the fluoroquinolone indication was justified, the association with another antibiotic was considered non-compliant in 20 % of cases (70/342), the choice of the molecule in 18 % (62/342), duration of treatment in 17 % (57/342), the dose in 13 % (45/342) and route of administration in 9 % (30/342). The requirements were entirely conform in 34 % of cases (160/475).
  
  
  CONCLUSIONS
  The results were communicated to each participating service with corrective actions and then this experience has been repeated in May 2009.
authors.affiliation: Service des maladies infectieuses et tropicales, hôpitaux de Brabois, CHU de Nancy, allée du Morvan, 54500 Vandœuvre-les-Nancy, France. edesmots@hotmail.com
authors.forename: E
authors.initials: E
authors.lastname: Desmots
authors.forename: B
authors.initials: B
authors.lastname: Demore
authors.forename: T
authors.initials: T
authors.lastname: Doco-Lecompte
authors.forename: C
authors.initials: C
authors.lastname: Burty
authors.forename: C
authors.initials: C
authors.lastname: Rabaud
authors.forename: T
authors.initials: T
authors.lastname: May
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology; D011307:Drug Prescriptions / Q000706:statistics & numerical data*; D004359:Drug Therapy, Combination; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D005602:France / Q000453:epidemiology; D019983:Guideline Adherence; D006748:Hospital Departments; D006753:Hospital Records; D006785:Hospitals, University / Q000706:statistics & numerical data*; D006801:Humans; D057970:Inappropriate Prescribing / Q000706:statistics & numerical data*; D008297:Male; D008485:Medical Audit; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000453:epidemiology; D012189:Retrospective Studies; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones